Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Yantai Zhenghai Biotechnology Co., Ltd. (300653.SZ)
Yantai, CN
Yantai Zhenghai Biotechnology Co., Ltd., founded in 2003 and based in Yantai, China, specializes in the innovation, manufacturing, and commercialization of regenerative medical materials across China. The company's product offerings include a bone repair material, which is a partially deproteinized substance derived from calf cancellous bone after undergoing a series of processes like decellularization and degreasing. It also provides membranes for oral cavity repair, specifically designed to address shallow soft tissue defects in the mouth. Under the "Heal-All" brand, it supplies biomembranes used in neurosurgical procedures to mend defects of the cerebral dura mater. Additionally, the "Heal-Full" brand encompasses skin repair membranes developed for treating wounds within the dermal layer.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.18% | -5.24% | -13.24% | -24.08% | -27.17% | -20.28% | -21.19% | -57.03% | -67.32% | +112.27% | +112.27% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 2 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%+0.3% Q1'26: -16.8% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%-38.7% Q1'26: -44.7% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%+27.8% Q1'26: +11.8% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%+24.2% ★ Q1'26: +17.0% (vs Q1'25)
-
ROIC Biotechnology: -16.1%+32.7% ★ Q1'26: +18.3% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%-0.2% ★ Q1'26: +0.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.00× ★ Q1'26: 0.09× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
215.54M
est: 216.00M (-0.2%)
|
279.81M
est: 267.00M (+4.8%)
|
293.28M
est: 338.00M (-13.2%)
|
400.18M
est: 388.00M (+3.1%)
|
493.18M
est.
|
433.22M
est: 387.17M (+11.9%)
|
413.65M
est: 387.17M (+6.8%)
|
363.23M
est: 397.59M (-8.6%)
|
364.14M
est: 350.71M (+3.8%)
|
389.58M
389.58M – 389.58M
+11.1% YoY
|
421.68M
421.68M – 421.68M
+8.2% YoY
|
452.69M
452.69M – 452.69M
+7.4% YoY
|
| EBITDA |
104.40M
est: 110.62M (-5.6%)
|
129.63M
est: 136.74M (-5.2%)
|
142.67M
est: 173.10M (-17.6%)
|
209.35M
est: 198.70M (+5.4%)
|
252.57M
est.
|
231.21M
est: 187.39M (+23.4%)
|
238.92M
est: 187.39M (+27.5%)
|
174.67M
est: 192.43M (-9.2%)
|
110.93M
est: 169.74M (-34.6%)
|
188.55M
188.55M – 188.55M
+11.1% YoY
|
204.09M
204.09M – 204.09M
+8.2% YoY
|
219.10M
219.10M – 219.10M
+7.4% YoY
|
| EBIT |
99.46M
est: 100.97M (-1.5%)
|
124.15M
est: 124.81M (-0.5%)
|
136.49M
est: 157.99M (-13.6%)
|
191.60M
est: 181.37M (+5.6%)
|
230.53M
est.
|
212.11M
est: 167.15M (+26.9%)
|
218.40M
est: 167.15M (+30.7%)
|
152.61M
est: 171.65M (-11.1%)
|
88.14M
est: 151.41M (-41.8%)
|
168.19M
168.19M – 168.19M
+11.1% YoY
|
182.05M
182.05M – 182.05M
+8.2% YoY
|
195.43M
195.43M – 195.43M
+7.4% YoY
|
| Net Income |
85.82M
est: 85.37M (+0.5%)
|
107.39M
est: 109.31M (-1.8%)
|
118.33M
est: 135.64M (-12.8%)
|
168.55M
est: 159.17M (+5.9%)
|
210.04M
est.
|
185.44M
est: 166.61M (+11.3%)
|
190.96M
est: 166.61M (+14.6%)
|
134.64M
est: 164.82M (-18.3%)
|
82.41M
est: 89.58M (-8.0%)
|
91.37M
91.37M – 91.37M
+2.0% YoY
|
102.12M
102.12M – 102.12M
+11.8% YoY
|
114.66M
114.66M – 114.66M
+12.3% YoY
|
| SGA |
99.38M
est: 64.72M (+53.5%)
|
130.40M
est: 80.00M (+63.0%)
|
125.29M
est: 101.28M (+23.7%)
|
151.39M
est: 116.26M (+30.2%)
|
147.77M
est.
|
145.55M
est: 138.89M (+4.8%)
|
132.04M
est: 138.89M (-4.9%)
|
146.65M
est: 142.63M (+2.8%)
|
129.79M
est: 125.81M (+3.2%)
|
139.75M
139.75M – 139.75M
+11.1% YoY
|
151.27M
151.27M – 151.27M
+8.2% YoY
|
162.39M
162.39M – 162.39M
+7.4% YoY
|
| EPS |
0.48
est: 0.48 (+0.9%)
|
0.59
est: 0.61 (-3.1%)
|
0.66
est: 0.76 (-12.6%)
|
0.94
est: 0.89 (+6.0%)
|
1.17
est.
|
1.28
est: 0.93 (+37.6%)
|
1.06
est: 0.93 (+14.0%)
|
0.75
est: 0.92 (-18.5%)
|
0.46
est: 0.50 (-8.0%)
|
0.51
0.51 – 0.51
+2.0% YoY
|
0.57
0.57 – 0.57
+11.8% YoY
|
0.64
0.64 – 0.64
+12.3% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-28 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-27 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-26 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-25 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-22 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-21 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-20 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-19 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-18 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-15 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-14 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-13 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-12 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-11 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-08 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-07 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-06 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 4/5 | 1/5 | 2/5 |
| 2026-04-30 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-29 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-28 | B | 3/5 | 3/5 | 3/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-27 | B | 3/5 | 3/5 | 3/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-24 | B | 3/5 | 3/5 | 3/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-23 | B | 3/5 | 3/5 | 3/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-22 | B | 3/5 | 3/5 | 3/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-21 | B | 3/5 | 3/5 | 3/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-20 | B | 3/5 | 3/5 | 3/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-17 | B | 3/5 | 4/5 | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-16 | B | 3/5 | 4/5 | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Donggang Zhang | Deputy General Manager | — | male |
| Kan Song | GM & Director | — | male |
| Li Zhao | Deputy GM, Secretary & Non-Independent Director | — | female |
| Xing Yang | Deputy General Manager | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 300653.SZ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
